The Challenge of Offering Long-Acting Antipsychotic Therapies: A Preliminary Discourse Analysis of Psychiatrist Recommendations for Injectable Therapy to Patients With Schizophrenia

被引:42
|
作者
Weiden, Peter J. [1 ]
Roma, Rebecca S. [2 ]
Velligan, Dawn I. [3 ]
Alphs, Larry [4 ]
DiChiara, Matthew [5 ]
Davidson, Brad [5 ]
机构
[1] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Div Schizophrenia & Related Disorders, San Antonio, TX 78229 USA
[3] Mercy Behav Hlth Pittsburgh, Community Treatment Team, Pittsburgh, PA USA
[4] Janssen Sci Affairs, Therapeut Area Lead Psychiat, Titusville, NJ USA
[5] Ogilvy CommonHlth Behav Insights, Parsippany, NJ USA
关键词
Antipsychotics; Delivery of Care; Schizophrenia; SHARED DECISION-MAKING; IN-OFFICE; PERSPECTIVES; ADHERENCE; DEPOT; COMMUNICATION; PERCEPTIONS; STRATEGIES; ATTITUDES; PROVIDER;
D O I
10.4088/JCP.13m08946
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: To characterize patterns of communication in the offer of long-acting injectable (LAI) antipsychotic medication made by psychiatrists to patients with schizophrenia by (1) examining the style and content of their interaction and (2) determining how these may have driven the ultimate response to recommendations for LAI therapy. Method: This was an observational study conducted at 10 community mental health centers in 3 waves from July 2010 to May 2011. The final dataset for discourse analysis was 33 recorded conversations in which a psychiatrist offered an injectable antipsychotic to a patient with schizophrenia. These visits were transcribed and analyzed by a team of linguists and social scientists. Results: Our primary finding is that, based on analyses of their language during the interview, psychiatrists presented LAI therapy in a negative light. Supporting this, 11 of 33 recommendations (33%) were accepted during the discussion, whereas in the postvisit interview, 27 of 28 patients (96%) who seemed to decline the initial recommendation said they actually would be willing to try LAI treatment. Conclusions: These data support a preliminary hypothesis that the relatively low use of injectable antipsychotic therapies in the United States relative to other parts of the world is not fully attributable to patient rejection of the injectable modality. Rather, psychiatrists' ambivalence regarding the value of LAIs may play a significant role in the perceived difficulty with patient acceptance of this recommendation. (c) Copyright 2015 Physicians Postgraduate Press, Inc.
引用
收藏
页码:684 / 690
页数:7
相关论文
共 50 条
  • [21] Long-Term Treatment With Long-Acting Injectable Antipsychotic in Schizophrenia Patients With and Without Dopamine Supersensitivity Psychosis
    Kogure, Masanobu
    Kanahara, Nobuhisa
    Kimura, Makoto
    Hanaoka, Shimpei
    Hirano, Hiromi
    Iyo, Masaomi
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2022, 42 (04) : 357 - 364
  • [22] Budget impact analysis of long-acting injectable antipsychotic treatments in schizophrenic patients in Sweden
    Tanova, N.
    Palimaka, S.
    Godet, A.
    Gannedahl, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S571 - S572
  • [23] Functional remission frequency in a French cohort of schizophrenia patients initiating treatment with long-acting injectable antipsychotic
    Bessieres, E.
    Bouju, S.
    Deal, C.
    Lancrenon, S.
    Llorca, P. M.
    Rouillon, F.
    Gorwood, P.
    EUROPEAN PSYCHIATRY, 2018, 48 : S105 - S105
  • [24] Cannabis use correlates with aggressive behavior and long-acting injectable antipsychotic treatment in Asian patients with schizophrenia
    Park, Seon-Cheol
    Oh, Hong Seok
    Tripathi, Adarsh
    Kallivayalil, Roy Abraham
    Avasthi, Ajit
    Grover, Sandeep
    Tanra, Andi Jayalangkara
    Kanba, Shigenobu
    Kato, Takahiro A.
    Inada, Toshiya
    Chee, Kok Yoon
    Chong, Mian-Yoon
    Lin, Shih-Ku
    Sim, Kang
    Xiang, Yu-Tao
    Tan, Chay Hoon
    Javed, Afzal
    Sartorius, Norman
    Shinfuku, Naotaka
    Park, Yong Chon
    NORDIC JOURNAL OF PSYCHIATRY, 2019, 73 (06) : 323 - 330
  • [25] Predictors of discontinuation and hospitalization during long-acting injectable antipsychotic treatment in patients with schizophrenia spectrum disorder
    Ucok, Alp
    Yagcioglu, Elif Anil
    Aydin, Memduha
    Kara, Ilayda Arjen
    Erbasan, Vefa
    Turkoglu, Ozge
    Ergun, Simge
    Chousein, Mourat Giousouf
    Oktar, Nilgun
    Ucar, Nihat
    Koroglu, Begum Saba
    Ozan, Elif
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2021, 36 (02) : 89 - 96
  • [26] Functional remission frequency in a French cohort of schizophrenia patients initiating treatment with long-acting injectable antipsychotic
    Bouju, S.
    Deal, C.
    Bessieres, E.
    Lancrenon, S.
    Llorca, P. M.
    Gorwood, P.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S419 - S420
  • [27] Duration of long-acting injectable antipsychotic treatment and reasons for its discontinuation: A chart review of patients with schizophrenia
    Kishi, Taro
    Sakuma, Kenji
    Okuya, Makoto
    Hatano, Masakazu
    Iwata, Nakao
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, 75 (07) : 240 - 241
  • [28] Comparisons of the effects of long-acting injectable monotherapy and combination therapy of long-acting injectable treatment with oral antipsychotics on treatment retention in patients with chronic schizophrenia
    Suzuki, Hidenobu
    Hibino, Hiroyuki
    Inoue, Yuichi
    Takaya, Atsuhiko
    ASIAN JOURNAL OF PSYCHIATRY, 2019, 39 : 112 - 113
  • [29] CHARACTERISTICS OF MEDICARE PATIENTS INITIATING LONG-ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS
    Grabner, M.
    Harris, K.
    Chiang, Y. Y.
    Teng, C. C.
    Dosreis, S.
    VALUE IN HEALTH, 2024, 27 (06) : S232 - S233
  • [30] Effectiveness of long-acting injectable risperidone in the Korean schizophrenia patients
    Ciwoniuk, M.
    Godlewska, B. R.
    Olajossy-Hilkesberger, L.
    Olajossy, M.
    Marmurowska-Michalowska, H.
    Limon, J.
    Landowski, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S456 - S457